Overview of diagnostic laboratory tests and diagnostic criteria for liver injury caused by Kampo medicine.

Background: Several studies have suggested that the known biomarkers and the diagnostic scales are unreliable for the diagnosis of Kampo‐induced liver injury (KMILI). Diagnostic Biomarkers: The lymphocyte transformation test (LTT) for Kampo medicines is likely to give false positive results, while the normal level of the basophil activation test (BAT) for diagnosing Kampo liver injury remains uncertain. Diagnostic Scale: Due to the lack of reliable biomarkers, diagnostic scales have been developed; however, the Digestive Disease Week [DDW])‐Japan criteria, which is widely used in Japan, has extremely low specificity for diagnosing KMILI. Conclusion: The diagnosis of KMILI remains challenging, and we eagerly await the development of reliable biomarkers for KMILI. [ABSTRACT FROM AUTHOR]